Continually Updated Clinical Reference
 
 
  All Sources     eMedicine     Medscape     Drug Reference     MEDLINE
 
You are in: eMedicine Specialties > Medicine, Ob/Gyn, Psychiatry, and Surgery > Cardiology

Aortic Regurgitation

Last Updated: July 17, 2006
Email to a Colleague
Synonyms and related keywords: aortic regurgitation, AR, aortic insufficiency, aortic disease, syphilitic aortitis, rheumatic valvulitis, aortic root disorders, Marfan disease, Marfan syndrome, degeneration of bicuspid aortic valves, bicuspid aortic valve degeneration, regurgitant aortic flow

  AUTHOR INFORMATION Section 1 of 11    Click here to go to the next section in this topic
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Pictures Bibliography

Author: Robert J Hilkert, MD, FACC, Clinical Associate Professor, Division of Cardiology, UMDNJ Robert Wood Johnson Medical School; Director, Cardiovascular RMRS, US Regional Medical and Research Specialists, Pfizer Global Pharmaceuticals

Coauthor(s): Hojun Yoo, MD, Chief Fellow, Department of Cardiology, Robert Wood Johnson University Hospital and UMDNJ

Robert J Hilkert, MD, FACC, is a member of the following medical societies: American College of Cardiology, American Heart Association, and American Society of Echocardiography

Editor(s): Martin Keane, MD, FACC, FAHA, Instructor and Assistant Professor, Department of Medicine, University of Pennsylvania School of Medicine; Director, Echocardiography Laboratory, Presbyterian Medical Center, University of Pennsylvania Health System; Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine; Steven J Compton, MD, FACC, FACP, Director of Cardiac Electrophysiology, Alaska Heart Institute, Providence and Alaska Regional Hospitals; Amer Suleman, MD, Consultant in Electrophysiology and Cardiovascular Medicine, Department of Internal Medicine, Division of Cardiology, Medical City Dallas Hospital; and Marschall S Runge, MD, PhD, Marion Covington Distinguished Professor of Medicine, Vice Dean for Clinical Affairs, School of Medicine, Chairman, Department of Medicine, University of North Carolina at Chapel Hill

Disclosure


  INTRODUCTION Section 2 of 11   Click here to go to the previous section in this topic Click here to go to the top of this page Click here to go to the next section in this topic
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Pictures Bibliography

Background: Primary disease of the aortic valve leaflets, the wall of the aortic root, or both may cause aortic regurgitation (AR). With the decline in the incidence of syphilitic aortitis and rheumatic valvulitis in the second half of the 20th century, various aortic root disorders such as Marfan disease and degeneration of bicuspid aortic valves have become the most common causes of AR.

Pathophysiology: Chronic AR produces left ventricular (LV) volume overload that leads to a series of compensatory changes, including LV enlargement and eccentric hypertrophy. The enlarged ventricle is more compliant and is well suited to deliver a large stroke volume. This occurs through rearrangement of myocardial fibers with the addition of new sarcomeres in series, causing the individual myocardial fibers to become longer. The dilated left ventricle can accommodate increased end-diastolic volume and deliver a larger stroke volume to compensate for the regurgitant aortic flow.

Wall thickness must increase to compensate for the increased ventricular dimensions. These compensatory changes are necessary to minimize or normalize wall stress according to the Laplace law (ie, wall tension/stress is related to the product of intraventricular pressure and radius divided by wall thickness). Increased wall thickness results from increased fiber diameter achieved by an increased number of sarcomeres in parallel. This type of hypertrophy observed in a volume-overload state usually is eccentric, as opposed to concentric hypertrophy observed in a pressure-overload state (ie, aortic stenosis). The increased myocardial mass in a hypertrophic heart enables individual sarcomeres to shorten to a normal degree.

As long as LV wall stress is maintained in the normal range, the LV preload reserve, contractility, and ejection fraction (EF) remain within the normal range. This is the chronic compensated stage. During this phase of the disease, most patients remain asymptomatic for decades because chronic AR generally is a slow and insidious disease with very low morbidity during a long asymptomatic phase.

With time, transition from a compensated to a decompensated state marks the progression of the disease. Progressive LV enlargement beyond that required by the valvular regurgitation occurs and is associated with a change of the left ventricle from an elliptical shape to a spherical shape.

The cause of this pathologic dilatation is not well understood, but loss of the collagen support system that acts as a skeleton for the heart may play a substantial role. These maladaptive changes in the interstitium of the heart are an intricate part of the LV hypertrophy process. In addition, diminished coronary flow reserve in this hypertrophied ventricle is thought to result in chronic subendocardial ischemia, even in the absence of epicardial coronary artery disease (CAD). Eventually, subendocardial necrosis and fibrosis occur, along with disruption of the collagen support system, with loss of LV systolic function. The neurohormonal response complicates the disease state further by its excessive growth stimuli, which are thought to be partially responsible for apoptosis (programmed cell death) of the remaining functional myocytes.

The vicious cycle continues until the decompensated stage develops over many years. Progressive LV enlargement, spherical LV shape, increased wall stress, decline in the contractility and EF, increased afterload, and decreased diastolic compliance with a rise in end-diastolic pressure characterize this stage. Frequently, development of congestive symptoms heralds this stage, but an insidious deterioration of ventricular function may occur without overt clinical signs.

In acute AR, the normal-sized left ventricle poorly tolerates the sudden large volume imposed on it. The left ventricle poorly accommodates the abrupt increase in end-diastolic volume, and diastolic filling pressure increases rapidly and dramatically. This leads to an acute decrease in forward stroke volume, and, although tachycardia develops as a compensatory mechanism to maintain cardiac output, this often is insufficient. The rise in LV filling pressure is transmitted to the left atrium, pulmonary veins, and pulmonary capillaries, leading to pulmonary edema and congestion. Acute AR usually is severe and rapidly leads to LV decompensation and/or failure and cardiogenic shock.

Frequency:

  • In the US: With the advent of Doppler echocardiogram studies, many cases of mild AR have been identified in the general population. In some studies, up to 8.5% of women and 13% of men were found to have some degree of AR. In surgical literature, up to 20% of all aortic valve surgeries are performed because of pure AR; however, aortic stenosis remains the most frequent indication for aortic valve replacement (AVR). Multiple logistic regression analysis revealed age and male gender to be predictors of AR.

Mortality/Morbidity: A long asymptomatic period with a relatively rapid downhill course after the onset of cardiac symptoms characterizes the natural history of chronic AR. Data from several studies concerning the natural history of chronic severe AR with normal LV function found the rate of progression to symptoms and/or LV dysfunction (LV ejection fraction [LVEF] <0.50) to be approximately 4.5% per year. The incidence rate of sudden cardiac death was very low, at less than 0.2% per year. Sudden cardiac death has generally not been considered an important risk for patients with AR who are asymptomatic and have normal LV function at rest. AVR can be postponed safely until the appearance of cardiac symptoms and/or LV dysfunction (LVEF <0.50) at rest. The prognosis of severe AR in asymptomatic patients with normal LV function remains excellent, but extra vigilance is required in monitoring these patients to ensure that the optimal time for surgical intervention is not overlooked. The risks associated with chronic severe AR are as
follows:

  • In asymptomatic patients with normal LV systolic function, the rate of progression to symptoms and/or LV dysfunction is less than 5% per year, the rate of progression to asymptomatic LV dysfunction is less than 2% per year, and the rate of sudden death is less than 0.2% per year.
  • For asymptomatic patients with LV systolic dysfunction, the rate of progression to cardiac symptoms is higher than 25% per year. In symptomatic patients, the mortality rate associated with angina is higher than 10% per year and, with congestive heart failure (CHF), is higher than 20% per year.
  • The rates of death, symptoms, or LV dysfunction in patients with LV end-systolic dimension (LVESD) greater than 55 mm is 19% per year, in patients with an LVESD of 40-49 mm is 6% per year, and in patients with LVESD less than 40 mm is 0% per year.

  • Because angina and dyspnea have long been considered an indication for surgery in this patient population, no large-scale recent studies exist of the natural history of symptomatic AR. These patients remain at high risk and mortality rates are estimated between 10% and 20%. For these reasons, the Guidelines for the Management of Patients with Valvular Heart Disease presented by the American College of Cardiology (ACC) and American Heart Association (AHA) recommend AVR for patients with class II-IV symptoms of angina or dyspnea and chronic severe AR.

Race: Incidence of AR is similar across various racial populations.

Sex: AR affects males and females equally.

Age: Significant AR can be found in patients of any age; however, the age at which AR becomes clinically significant varies based on etiology. Patients with Marfan disease and those with bicuspid aortic valve problems tend to present earlier in life and generally are free of disability from LV dysfunction at the time of presentation. If left untreated, significant cardiac symptoms commonly appear in the fifth decade of life and beyond, usually after considerable cardiomegaly and myocardial dysfunction have occurred.


  CLINICAL Section 3 of 11   Click here to go to the previous section in this topic Click here to go to the top of this page Click here to go to the next section in this topic
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Pictures Bibliography

History: The natural history of AR is a slow and insidious disease process, with many patients remaining asymptomatic for decades. In asymptomatic patients, a cardiac murmur found during a routine medical examination often leads to diagnosis; however, once cardiac symptoms develop, clinical deterioration is rapid.

  • The principal symptoms associated with severe AR are exertional dyspnea, orthopnea, and paroxysmal nocturnal dyspnea. These symptoms appear when pulmonary venous pressure is elevated in association with significant cardiomegaly and myocardial dysfunction. These changes occur late in the natural history of the disease.
  • Angina pectoris may occur without CAD because coronary perfusion is inadequate to meet the demands of the enlarged and hypertrophic left ventricle. Less commonly, aortitis can involve the origin of the coronary arteries, leading to angina.
  • Palpitation is a common complaint associated with a hyperdynamic and tachycardic left ventricle in significant AR. Palpitation also may be due to frequent premature ventricular contraction.
  • Syncope is an uncommon symptom associated with AR.
  • Sudden cardiac deaths have been relatively rare in asymptomatic patients with normal LV function (<0.2% per y).
  • In contrast to chronic AR, symptoms of acute AR (commonly from infective endocarditis, aortic dissection, or trauma) develop rapidly and are very poorly tolerated. In acute AR, the normal-sized ventricle is unable to adapt to the sudden increase in regurgitant volume, in addition to the normal left atrial inflow. Thus, patients develop pulmonary congestion associated with LV failure and, possibly, cardiogenic shock.

Physical:

  • Hemodynamically severe AR causes a widened pulse pressure, often greater than 100 mm Hg, associated with a low diastolic pressure, often less than 60 mm Hg.
  • The de Musset sign is when patients' heads frequently bob with each heartbeat.
  • The Corrigan pulse is when patients' pulses are of the water-hammer or collapsing type, with abrupt distention and quick collapse.
  • The Quincke sign is when light transmitted through the patient's fingertip shows capillary pulsations.
  • The Hill sign is when popliteal cuff systolic pressure exceeds brachial cuff pressure by more than 60 mm Hg.
  • The Duroziez sign is when a systolic murmur is heard over the femoral artery when compressed proximally and when a diastolic murmur is heard when the femoral artery is compressed distally.
  • The Müller sign is systolic pulsations of the uvula.
  • The Traube sign (also called pistol-shot sounds) refers to booming systolic and diastolic sounds heard over the femoral artery.
  • The apical impulse in chronic AR is diffuse, hyperdynamic, and displaced inferiorly and leftward.
  • S3 gallop correlates with development of LV dysfunction.
  • The typical diastolic murmur of AR has a decrescendo shape. A high-frequency early diastolic murmur often occurs in mild AR, whereas a rough holodiastolic or decrescendo diastolic murmur occurs more commonly in severe AR. The volume and velocity of blood across the incompetent aortic valve tapers off in mid-to-last diastole as the aortic and LV pressures equilibrate. The diastolic murmur of AR is usually best heard adjacent to the sternum in the second to fourth left intercostal space. A concomitant systolic ejection murmur is common in moderate-to-severe AR
  • The murmur associated with acute AR may not be impressive. If cardiac decompensation is present, the diastolic murmur of acute AR may be very soft and surprisingly short.
  • Antegrade flow across the mitral valve is thought to cause an Austin Flint murmur, which is a mid- and late-diastolic apical low-frequency murmur or rumble. The rumble occurs during rapid closure of the mitral valve as flow velocity is increasing across the valve and LV diastolic pressure is rising rapidly because of severe aortic reflux. Its presence indicates severe AR.

Causes:

  • Acute aortic regurgitation
    • Infective endocarditis may lead to destruction or perforation of the aortic valve leaflet. The vegetation can also interfere with proper coaptation of the valve leaflets and can sometimes lead to frank prolapse or flail of a leaflet.
    • In acute ascending aortic dissection (type A), the retrograde proximal dissection flap undermines the commissural suspensions of the aortic valve leaflets. Varying levels of aortic malcoaptation and prolapse occur.
    • Prosthetic valve malfunction can lead to AR.
    • Chest trauma may lead to a tear in the ascending aorta and disruption of the aortic valve support apparatus.
  • Chronic aortic regurgitation
    • While a congenital bicuspid aortic valve often leads to progressive aortic stenosis, incomplete closure or prolapse can also lead to significant regurgitant flow across the valve. This common congenial lesion remains the most common cause of isolated AR requiring aortic valve surgery. Histologic abnormalities of the bicuspid root frequently lead to proximal aortic dilatation and further exacerbation of AR.
    • Connective tissue disorders syndrome, including Marfan syndrome, Ehlers-Danlos syndrome, floppy aortic valve, aortic valve prolapse, sinus of Valsalva aneurysm, and aortic annular fistula can all lead to significant chronic AR. The use of diet drugs such as fenfluramine and dexfenfluramine (commonly referred to as Phen-Fen) may lead to chronic AR, although these data remain controversial at this time.
    • Representative of connective tissue disorders, Marfan syndrome is a common cause of severe AR that requires intervention. This disorder is associated with dilated sinuses of Valsalva, progressing to aortic dilatation and AR. These patients are also at very high risk for aortic dissection, depending on the size of the ascending aorta.
    • Rheumatic fever was a common cause of AR in the first half of the 20th century. The cusps become thickened with fibrous tissues and retract, which causes central valvular regurgitation. Most commonly, some fusion of the cusps occurs, resulting in some degree of aortic stenosis and regurgitation. Associated rheumatic mitral valve disease is also very common.
    • Syphilitic aortitis leads to dilatation of the ascending aorta. The aortic annulus becomes dilated, and coaptation of the cusps is lost.
    • Takayasu arteritis involves the aorta and its major branches. AR may complicate type I and type III of this disease.
    • Ankylosing spondylitis leads to shortening and thickening of the aortic valve cusps and dilatation of the aortic root.
    • Reiter syndrome presents similarly to ankylosing spondylitis. Dilatation of the aortic root and associated AR occurs. Reiter syndrome may involve the coronary ostium rarely, producing angina.
    • Rheumatoid arthritis can produce granulomata involving the valve leaflets and rings. The central portion of the leaflets is usually involved, with sparing of the peripheral portions.
    • Systemic lupus erythematosus (SLE) is associated with Libman-Sacks endocarditis, and these verrucous vegetations can produce mitral and aortic regurgitation. Distinct from endocarditis, SLE can produce valvulitis, leading to thickened, calcific, and dysfunctional valves.
    • Behçet disease is a diffuse aortitis, often leading to proximal aortic dilatation and severe AR.
  DIFFERENTIALS Section 4 of 11   Click here to go to the previous section in this topic Click here to go to the top of this page Click here to go to the next section in this topic
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Pictures Bibliography

Mitral Stenosis
Pulmonic Regurgitation
Tricuspid Stenosis


Quick Find
Author Information
Introduction
Clinical
Differentials
Workup
Treatment
Medication
Follow-up
Miscellaneous
Pictures
Bibliography

Click for related images.

Related Articles
Mitral Stenosis

Pulmonic Regurgitation

Tricuspid Stenosis


Patient Education
Click here for patient education.



  WORKUP Section 5 of 11   Click here to go to the previous section in this topic Click here to go to the top of this page Click here to go to the next section in this topic
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Pictures Bibliography

Lab Studies:

  • No specific laboratory blood tests are required in the workup of AR. However, serologic testing may be required when attempting to distinguish the various etiologies of AR.

Imaging Studies:

  • Two-dimensional echocardiography and Doppler
    • M-mode features of AR include the following:

      • Diastolic flutter of the mitral valve (can be both anterior and posterior mitral valve leaflet)

      • Diastolic flutter of the aortic valve

      • Premature closure of the mitral valve (severe AR)

      • Premature opening of the aortic valve (severe elevated LV end-diastolic pressure)

      • Diastolic LV septal fluttering

      • LV volume overload (hyperkinesis of the LV walls with LV dilatation)

      • LVESD (>55 mm indicates poorer surgical outcome)
    • On 2-dimensional echocardiography, look for the following features:

      • Flail aortic valve

      • Dilatation of the sinuses of Valsalva (particularly in patients with Marfan syndrome or bicuspid aortic valve problems)

      • Ascending aortic aneurysm

      • Incomplete closure of the aortic valve cusps on the parasternal short-axis view of the aortic valve

      • High-frequency diastolic fluttering of the anterior leaflet of the mitral valve during diastole

      • Reverse doming of the anterior mitral valve leaflet

      • LV volume overload pattern

      • Measurements of LV end-diastolic and end-systolic dimensions and volumes, shortening fractions, and EFs - Critical in determining the optimal time for valve replacement

      • Measurement of aortic regurgitant fraction, regurgitant orifice size, and regurgitant volumes - Now available with Doppler echocardiography
    • Color-flow Doppler should be used as follows:

      • Determine the regurgitant jet height and/or LV outflow tract (LVOT) height in the parasternal long-axis view (mild [1+] <25%, moderate [2+] 25-46%, moderately severe [3+] 47-64%, severe [4+] >65%).

      • Determine the regurgitant jet area and/or LVOT area in the parasternal short-axis view of the aortic valve (mild [1+] <20%, moderate [2+] 20-40%, moderately severe [3+] 40-60%, severe [4+] >60%).

      • Proximal acceleration (flow convergence) indicates aortic insufficiency is grade 3+ or 4+.
    • Continuous-wave Doppler should be used as follows:

      • Determine the spectral strength of the regurgitant jet. Grade 1+ produces spectral tracing stain sufficient for detection but is not enough for clear delineation. In grade 2+, complete spectral tracing can barely be seen. In grade 3+, distinct darkening of spectral tracing is visible, but density is less than antegrade flow. Grade 4+ produces dark-stained spectral tracing.

      • Determine the slope of the aortic insufficiency spectral display. In general, steeper slopes indicate more severe aortic insufficiency.

      • Determine the pressure half-time of the aortic insufficiency spectral display. In general, a pressure half-time less than or equal to 300 m/s indicates significant aortic insufficiency.
    • Pulsed-wave Doppler should be used as follows:

      • The pulse-wave mapping technique is used mostly prior to color Doppler.

      • Velocity of more than 1.5 m/s is consistent with marked AR.

      • Mitral inflow has a restrictive filling pattern.

      • Reversal of flow in the descending thoracic aorta and/or abdominal aorta indicates that aortic insufficiency is moderately severe (3+ or 4+). This phenomenon requires careful placement of the sample volume in the descending aorta, distal to the takeoff of the left subclavian artery. The flow in the descending aorta may also be seen with color-flow Doppler, although this method is more prone to error.
  • Radionuclide imaging should be used as follows:
    • Radionuclide angiography findings can help determine the AR regurgitant fraction and the left-to-right ventricular stroke volume ratio. An accurate noninvasive assessment of the severity of AR can be determined if concomitant mitral regurgitation, tricuspid regurgitation, or pulmonary regurgitation is not present.
    • Left-to-right ventricular stroke volume ratio of 2 or more denotes severe AR.
  • MRI or ultrafast CT scanning are as follows:
    • These techniques can provide accurate measurements of regurgitant volumes, ventricular end-systolic and diastolic volumes, ejection fraction, ventricular mass, and the regurgitant orifice.
    • These techniques are not as well validated as echocardiography and may not be as widely available.
  • Chest radiograph findings are as follows:
    • In acute AR, little cardiac enlargement may be present, but, in chronic AR, enlargement is marked.
    • Dilatation of the ascending aorta may suggest that aortic root disease is responsible for AR.
    • Pulmonary congestion can be observed in patients who have developed LV dysfunction or in those with acute AR.

Other Tests:

  • Electrocardiography findings can reveal the following, although they are not an accurate predictor of the severity of AR:
    • LV hypertrophy
    • Left axis deviation
    • Left atrial enlargement
    • LV volume overload pattern (prominent Q waves in leads I, aVL, and V3 to V6 and relatively small r waves in V1)
    • LV conduction defect (late in disease process)
  • Exercise treadmill testing
    • Assessment of functional capacity and symptomatic responses in patients with a history of equivocal symptoms
    • Evaluation of symptoms and functional capacity before participation in athletic activities

Procedures:

  • Cardiac catheterization
    • Indications

      • This should be performed for coronary angiography studies before AVR in patients at risk for CAD, including men older than 35 years, premenopausal women older than 35 years with coronary risk factors, and postmenopausal women.

      • It can be used to assess the severity of regurgitation when noninvasive test results are inconclusive or discordant with clinical findings regarding the severity of regurgitation or the need for surgery.

      • Use cardiac catheterization to assess LV function when noninvasive test results are inconclusive or discordant with clinical findings regarding LV dysfunction and the need for surgery in patients with severe AR.
    • Qualitative assessment (aortic angiogram)

      • In mild AR (1+), a small amount of contrast enters the left ventricle during diastole and clears with each systole.

      • In moderate AR (2+), more contrast enters with each diastole, and faint opacification of the entire LV chamber occurs.

      • In moderately severe AR (3+), the LV chamber is well opacified and equal in density when compared with the ascending aorta.

      • In severe AR (4+), complete dense opacification of the LV chamber occurs on the first beat and the left ventricle is more densely opacified than the ascending aorta.
    • Simultaneous aortic and LV pressure tracing (signs of severe AR)

      • Wide pulse pressure may be present.

      • Brisk aortic pressure upstroke can be observed.

      • LV diastolic pressure increases rapidly.

      • Near equilibration of aortic and LV pressure occurs at diastole.
Histologic Findings: Histological changes in the left ventricle include fiber hypertrophy and increased interstitial fibrous tissue. In decompensated LV, disruption of the collagen support system and subsequent fiber layer slippage occur. In the subendocardium, evidence of necrosis, replacement fibrosis, and apoptosis is abundant.

Recent data suggest that patients with a wide variety of congenital heart lesions (including bicuspid aortic valves) have underlying distortion of the aortic root. These patients were found to have abnormalities of smooth muscle, elastin, collagen, and ground substance in the ascending aorta over a wide variety of ages. Programmed cell death (apoptosis) of neural crest derivative cells within the proximal aorta has also been demonstrated in patients with bicuspid aortic valve problems.

These aortic abnormalities predispose to progressive proximal aortic dilatation, aneurysm formation, or aortic rupture. These proximal aortic changes occur regardless of the underlying severity of aortic valvular disease and can be observed in patients with nonregurgitant bicuspid valves.

  TREATMENT Section 6 of 11   Click here to go to the previous section in this topic Click here to go to the top of this page Click here to go to the next section in this topic
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Pictures Bibliography

Medical Care:
Medical vs Surgical Treatment: Medical therapy is appropriate for many patients with mild to moderate chronic AR. The appropriate use of vasodilators, as described below, is associated with improvement in symptoms and is thought to slow the development of LV enlargement and dysfunction and the need for surgery. That said, physicians treating patients with chronic AR must be attentive to any changes that suggest worsening LV function and the need for surgery. Subjective reporting of exercise tolerance by patients is often unreliable. In patients with borderline AR, formal exercise testing on an annual basis may be useful. Annual echocardiography to assess LV size and function is also useful. As with mitral valve regurgitation, patients should be referred for surgical evaluation before irreversible LF dysfunction has occurred.

Patients with acute, significant AR represent an entirely different group. Surgical treatment is almost always indicated and medical therapy (typically using intravenous medications titrated to blood pressure, as described below) is recommended only as an interim measure.

Medical Care: Vasodilator therapy is designed to optimize LV loading conditions and achieve a favorable remodeling process through systolic unloading and reduction in regurgitant volume. Treat asymptomatic patients with chronic severe AR and dilated but normal LV systolic function medically, and monitor their cases for development of indications for AVR. Patients with mild AR and normal LV size require no therapy other than endocarditis prophylaxis.

Surgical Care: Surgical treatment of AR almost always requires replacement of the diseased valve with a prosthetic valve. The surgical mortality rate for AVR probably is 3%, although the mortality rate may be higher if patients also need coronary artery bypass grafts. In addition, the long-term complications of prosthetic valves need to be considered.

  • AVR is indicated in patients with normal systolic function (defined as EF >0.50 at rest) who have New York Heart Association (NYHA) functional class III or IV symptoms. Also consider patients with Canadian Heart Association functional class II-IV angina pectoris for surgery. In many patients with NYHA functional class II dyspnea, the etiology of symptoms often is unclear and clinical judgment is required.
  • Patients with NYHA functional class II, III, or IV symptoms and with mild-to-moderate LV systolic dysfunction (EF 0.25-0.49) should undergo AVR. Patients with functional class IV symptoms have worse postoperative survival rates and a lower likelihood of recovery of systolic function when compared to patients with less severe symptoms, but AVR improves ventricular loading conditions and expedites subsequent management of LV dysfunction.
  • Symptomatic patients with severe LV dysfunction (EF <0.25) pose difficult management issues. Most patients develop irreversible myocardial damage and may not show improved LV function or NYHA functional class after AVR; however, some patients may gain meaningful recovery of LV function. Surgery carries an operative mortality rate of approximately 10%, but medical therapy alone carries a mortality rate of higher than 20% per year; thus, high-risk AVR may be a viable option when compared to the even worse prognosis associated with medical therapy alone.
  • Asymptomatic patients with evidence of LV systolic dysfunction (EF <0.50) should undergo AVR. The postoperative recovery of LV function and survival is strongly associated with preoperative LV function; thus, do not delay AVR for patients with evidence of LV dysfunction.
  • Asymptomatic patients with severe AR and normal LV function but with severe LV dilatation (end-diastolic dimension >75 mm or end-systolic dimension >55 mm) should undergo AVR. These patients tend to progress to symptomatic or LV dysfunction rapidly. Postoperative survival and reduction of LV dimension in this subgroup of patients are excellent.
  • Preoperative predictors of poor postoperative survival and LV function include the following:
    • LVESD greater than 55 mm
    • LVEF less than 0.50
    • NYHA CHF class III, IV
    • Duration of CHF symptoms longer than 12 months

Consultations:

  • Cardiologist
  • Cardiothoracic surgeon

Diet: Place patients on a low-sodium diet with fluid restriction when CHF symptoms appear.

Activity: Asymptomatic patients with normal LV systolic function may participate in all forms of normal daily physical activity, including mild forms of exercise and, in some cases, competitive athletics; however, isometric exercise (eg, weight lifting) should be avoided. Patients with evidence of LV dysfunction or low cardiac reserve should not engage in vigorous sports or heavy exertion.
  MEDICATION Section 7 of 11   Click here to go to the previous section in this topic Click here to go to the top of this page Click here to go to the next section in this topic
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Pictures Bibliography

Vasodilator therapy has reduced severity of AR and LV volume and mass successfully, postponing the need for surgical intervention.

Drug Category: Angiotensin-converting enzyme inhibitors -- Competitive inhibitors of angiotensin-converting enzyme (ACE). Reduce angiotensin II levels, decreasing aldosterone secretion.
Drug Name
Enalapril (Vasotec) -- ACE-I produces a small increase in EF and significant decrease in LV volume and mass. Effective vasodilator therapy requires adjustment of dosage to achieve a decrease in arterial pressure.
Adult Dose5 mg PO bid for 2 wk initially; if hemodynamically stable, increase to 10 mg PO bid for 2 wk, then to 20 mg PO bid maintenance
Pediatric DoseNot established
ContraindicationsDocumented hypersensitivity; second or third trimester pregnancy, breastfeeding, history of angioneurotic edema, significant renal artery stenosis
InteractionsNSAIDs may reduce hypotensive effects; ACE inhibitors may increase digoxin, lithium, and allopurinol levels; rifampin decreases levels; probenecid may increase levels; hypotensive effects of ACE inhibitors may be enhanced when administered concurrently with diuretics
Pregnancy C - Safety for use during pregnancy has not been established.
PrecautionsPregnancy category D in second and third trimester of pregnancy; caution in renal impairment, valvular stenosis, severe CHF, or angioedema; oliguria, seizures, and unpredictable effects on BP may occur in children
Drug Category: Calcium channel blockers -- Inhibit movement of calcium ions across the cell membrane, depressing both impulse formation (automaticity) and conduction velocity.
Drug Name
Nifedipine (Procardia) -- Produces significant fall in arterial pressure, reduces LV volume and mass, increases EF, and delays need for AVR in asymptomatic patients with severe AR and normal LV systolic function. Effective vasodilator therapy requires adjustment of dosage to decrease arterial pressure.
Adult Dose10 mg PO bid initially, then titrate to 20 mg PO bid
Pediatric DoseNot established
ContraindicationsDocumented hypersensitivity; CHF, cardiogenic shock, acute MI
InteractionsAlcohol, cimetidine, and ranitidine increase bioavailability and effect; antihypertensive medications produce an additive effect; may decrease quinidine levels; may increase digoxin levels; rifampin, phenobarbital, and phenytoin decrease effects
Pregnancy C - Safety for use during pregnancy has not been established.
PrecautionsRenal or hepatic dysfunction; breastfeeding; may cause lower extremity edema; allergic hepatitis is rare
Drug Category: Cardiac glycosides -- Inhibit sodium-potassium ATPase. Inhibition of the enzyme leads to an increase in the intracellular concentration of sodium and calcium. Vagomimetic action leads to reduced activity of sympathetic nervous system.
Drug Name
Digoxin (Lanoxin) -- Pharmacologic consequences include an increase in the force and velocity of myocardial systolic contraction (positive inotropic action) and slowing of the heart rate and decreased conduction velocity through the AV node (vagomimetic effect). Use in patients with heart failure is associated with 25% reduction in the frequency of hospitalization for heart failure. Use is not associated with mortality benefit.
Adult Dose<70 years and good renal function: 0.25 mg PO qd general initial dose
>70 years or impaired renal function: 0.125 mg PO qd general initial dose
Marked renal impairment: 0.0625 mg general initial dose
0.4-0.6 mg if rapid digitalization with IV loading is needed; produces detectable effect in 5-30 min; 0.1- to 0.3-mg additional doses may be administered cautiously at 6- to 8-h intervals until clinical evidence of an adequate effect
Pediatric DoseAdjust loading and daily maintenance dose by body weight
Digitalization in infants and children not generally recommended; suggested doses are as follows:
TDD
Premature infants: 0.02-0.03 mg/kg if tab; 0.015-0.025 mg/kg if cap, IV, or IM in divided doses
Full-term infants: 0.025-0.035 mg/kg if tab; 0.02-0.03 if cap, IV, or IM in divided doses
1-24 months: 0.035-0.06 mg/kg if tab; 0.03-0.05 mg/kg if cap, IV, or IM in divided doses
2-5 years: 0.03-0.04 mg/kg if tab; 0.025-0.035 mg/kg if cap, IV, or IM in divided doses
5-10 years: 0.02-0.035 mg/kg if tab; 0.015-0.030 mg/kg if cap, IV, or IM in divided doses
>10 years: 0.01-0.015 mg/kg if tab; 0.008-0.012 if cap, IV, or IM in divided doses
May accomplish digitalization by giving half TDD in first dose followed by 2 doses that are one fourth TDD given at 8- to 12-h intervals
Maintenance dose
Premature infants: 0.005-0.0075 mg/kg if tab; 0.004-0.006 mg/kg if cap, IV, or IM divided q12h
Full-term infants: 0.006-0.01 mg/kg if tab; 0.005-0.008 if cap, IV, or IM divided q12h
1-24 months: 0.010-0.015 mg/kg if tab; 0.0075-0.012 mg/kg if cap, IV, or IM divided q12h
2-5 years: 0.0075-0.01 mg/kg if tab; 0.006-0.009 mg/kg if cap, IV, or IM divided q12h
5-10 years: 0.005-0.01 mg/kg if tab; 0.004-0.008 mg/kg if cap, IV, or IM divided q12h
>10 years: 0.0025-0.005 mg/kg if tab; 0.002-0.003 if cap, IV, or IM qd or divided q12h
See prescribing information in PDR for more detailed information
ContraindicationsDocumented hypersensitivity (hypersensitivity reaction to other digitalis preparations usually constitutes a contraindication to digoxin), ventricular fibrillation
InteractionsPotassium-depleting diuretics are a major contributing factor to digitalis toxicity; quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise serum digoxin concentrations because of a reduction in clearance and/or in volume of distribution of drug, digitalis intoxication may result
Pregnancy C - Safety for use during pregnancy has not been established.
PrecautionsBecause digoxin slows sinoatrial and AV conduction, drug commonly prolongs PR interval; may cause severe sinus bradycardia or sinoatrial block in preexisting sinus node disease, and may cause advanced or complete heart block in preexisting incomplete AV block; patients with paroxysmal atrial fibrillation or flutter and a coexisting accessory AV pathway have developed increased antegrade conduction across the accessory pathway bypassing the AV node, leading to a very rapid ventricular response or ventricular fibrillation after use; unless conduction down the accessory pathway has been blocked (either pharmacologically or by surgery), do not prescribe digoxin to such patients
Drug Category: Diuretics -- Increase urine flow. These agents are ion transport inhibitors that decrease the reabsorption of sodium at different sites in the nephron. Diuretics have major clinical uses in managing disorders involving abnormal fluid retention (edema) or in treating hypertension, in which their diuretic action causes decreased blood volume.
Drug Name
Furosemide (Lasix) -- Like torsemide and bumetanide, is a potent loop diuretic. Compared to all other classes of diuretics, these drugs have the highest efficacy in mobilizing sodium and chloride from the body. Loop diuretics inhibit the Na+, K+, and Cl- cotransport in the ascending limb of the loop of Henle. Furosemide and other loop diuretics are indicated in treatment of edema associated with CHF, cirrhosis of the liver, and renal disease, including nephrotic syndrome. May be used to treat hypertension alone or in combination with other antihypertensive agents.
Adult DoseIndividualize according to patient response to gain maximal therapeutic response and to determine the minimal dose needed to maintain that response
20-80 mg PO administered as a single dose is usual initial dose; repeat or increase 6-8 h later if needed; dose may be titrated carefully up to 600 mg/d in patients with clinically severe edematous states; at higher doses, careful clinical observation and close laboratory monitoring are particularly important
Pediatric Dose2 mg/kg PO administered as a single dose is usual dose in infants and children; dosage may be increased by 1-2 mg/kg no sooner than 6-8 h after previous dose if needed; not to exceed 6 mg/kg
ContraindicationsDocumented hypersensitivity; anuria
InteractionsMay increase ototoxic potential of aminoglycoside antibiotics, especially in impaired renal function
Pregnancy C - Safety for use during pregnancy has not been established.
PrecautionsExcessive diuresis may cause dehydration and blood volume reduction with circulatory collapse; observe all patients receiving furosemide therapy for signs or symptoms of fluid or electrolyte imbalance; asymptomatic hyperuricemia can occur, and gout may be precipitated
Drug Category: Direct-acting adrenergic agonists -- Act directly on alpha- and beta-receptors, producing effects similar to those that occur following stimulation of sympathetic nerves or release of the hormone epinephrine from the adrenal medulla.
Drug Name
Dobutamine (Dobutrex) -- Synthetic direct-acting catecholamine and beta-receptor agonist. Increases cardiac contractility and output in CHF. At therapeutic dose, mainly an inotropic agent, while producing comparatively mild chronotropic and vasodilative effects. As compared to other sympathomimetic drugs, does not significantly increase myocardial oxygen demands, which is its major advantage compared to other direct-acting catecholamines.
Adult DoseStart at low rate (1 mcg/kg/min IV infusion) titrated at intervals of few minutes guided by the patient's response, including systemic blood pressure, urine flow, frequency of ectopic activity, heart rate, and, if possible, measurement of cardiac output, central venous pressure, and/or pulmonary capillary wedge pressure
2-20 mcg/kg/min IV usual range, but clinical response dictates optimal infusion rate
Pediatric DoseNot established
ContraindicationsDocumented hypersensitivity, idiopathic hypertrophic subaortic stenosis
InteractionsAnimal studies indicate that may be ineffective if patient recently received a beta-blocking drug; in this case, peripheral vascular resistance may increase
Pregnancy B - Usually safe but benefits must outweigh the risks.
PrecautionsDuring administration, monitor ECG and blood pressure continuously; monitor pulmonary wedge pressure and cardiac output whenever possible to aid in safety and efficacy of infusion
  FOLLOW-UP Section 8 of 11   Click here to go to the previous section in this topic Click here to go to the top of this page Click here to go to the next section in this topic
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Pictures Bibliography

Further Inpatient Care:

Further Outpatient Care:

In/Out Patient Meds:

Transfer:

Deterrence/Prevention:

Complications:

Prognosis:

Patient Education:

  MISCELLANEOUS Section 9 of 11   Click here to go to the previous section in this topic Click here to go to the top of this page Click here to go to the next section in this topic
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Pictures Bibliography

Medical/Legal Pitfalls:

  • Antibiotic prophylaxis for prevention of aortic valve endocarditis is an important part of continuing medical care of patients with significant AR.
  • Intra-aortic balloon pump use for hemodynamic support is contraindicated in patients with hemodynamically significant (ie, moderate or severe) AR.
  • Symptomatic patients (NYHA class III, IV) with severe AR should undergo valve replacement, regardless of LV systolic function.
  PICTURES Section 10 of 11   Click here to go to the previous section in this topic Click here to go to the top of this page Click here to go to the next section in this topic
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Pictures Bibliography

Caption: Picture 1. The light blue jet represents the aortic regurgitant flow on this 2-dimensional color Doppler echocardiogram showing severe aortic regurgitation.
Click to see larger pictureClick to see detailView Full Size Image
Picture Type: Image
  BIBLIOGRAPHY Section 11 of 11   Click here to go to the previous section in this topic Click here to go to the top of this page
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Pictures Bibliography

  • Bekeredjian R, Grayburn PA: Valvular heart disease: aortic regurgitation. Circulation 2005 Jul 5; 112(1): 125-34[Medline].
  • Bonow RO, Dodd JT, Maron BJ, et al: Long-term serial changes in left ventricular function and reversal of ventricular dilatation after valve replacement for chronic aortic regurgitation. Circulation 1988 Nov; 78(5 Pt 1): 1108-20[Medline].
  • Bonow RO, Picone AL, McIntosh CL, et al: Survival and functional results after valve replacement for aortic regurgitation from 1976 to 1983: impact of preoperative left ventricular function. Circulation 1985 Dec; 72(6): 1244-56[Medline].
  • Bonow RO, Rosing DR, McIntosh CL, et al: The natural history of asymptomatic patients with aortic regurgitation and normal left ventricular function. Circulation 1983 Sep; 68(3): 509-17[Medline].
  • Bonow RO, Nikas D, Elefteriades JA: Valve replacement for regurgitant lesions of the aortic or mitral valve in advanced left ventricular dysfunction. Cardiol Clin 1995 Feb; 13(1): 73-83, 85[Medline].
  • Bonow RO, Carabello B, de Leon AC, et al: ACC/AHA Guidelines for the Management of Patients With Valvular Heart Disease. Executive Summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Valvul. J Am Coll Cardiol 1998; 32: 1504-15.
  • Borer JS, Hochreiter C, Herrold EM, et al: Prediction of indications for valve replacement among asymptomatic or minimally symptomatic patients with chronic aortic regurgitation and normal left ventricular performance. Circulation 1998 Feb 17; 97(6): 525-34[Medline].
  • Borer JS, Bonow RO: Contemporary approach to aortic and mitral regurgitation. Circulation 2003 Nov 18; 108(20): 2432-8[Medline].
  • Clark DG, McAnulty JH, Rahimtoola SH: Valve replacement in aortic insufficiency with left ventricular dysfunction. Circulation 1980 Feb; 61(2): 411-21[Medline].
  • Daniel WG, Hood WP, Siart A, et al: Chronic aortic regurgitation: reassessment of the prognostic value of preoperative left ventricular end-systolic dimension and fractional shortening. Circulation 1985 Apr; 71(4): 669-80[Medline].
  • Evangelista A, Tornos P, Sambola A, et al: Long-term vasodilator therapy in patients with severe aortic regurgitation. N Engl J Med 2005 Sep 29; 353(13): 1342-9[Medline].
  • Fioretti P, Roelandt J, Sclavo M, et al: Postoperative regression of left ventricular dimensions in aortic insufficiency: a long-term echocardiographic study. J Am Coll Cardiol 1985 Apr; 5(4): 856-61[Medline].
  • Forman R, Firth BG, Barnard MS: Prognostic significance of preoperative left ventricular ejection fraction and valve lesion in patients with aortic valve replacement. Am J Cardiol 1980 Jun; 45(6): 1120-5[Medline].
  • Gaasch WH, Andrias CW, Levine HJ: Chronic aortic regurgitation: the effect of aortic valve replacement on left ventricular volume, mass and function. Circulation 1978 Nov; 58(5): 825-36[Medline].
  • Gaasch WH, Carroll JD, Levine HJ, Criscitiello MG: Chronic aortic regurgitation: prognostic value of left ventricular end- systolic dimension and end-diastolic radius/thickness ratio. J Am Coll Cardiol 1983 Mar; 1(3): 775-82[Medline].
  • Goldschlager N, Pfeifer J, Cohn K, et al: The natural history of aortic regurgitation. A clinical and hemodynamic study. Am J Med 1973 May; 54(5): 577-88[Medline].
  • Greenberg B, Massie B, Bristow JD, et al: Long-term vasodilator therapy of chronic aortic insufficiency. A randomized double-blinded, placebo-controlled clinical trial. Circulation 1988 Jul; 78(1): 92-103[Medline].
  • Greves J, Rahimtoola SH, McAnulty JH, et al: Preoperative criteria predictive of late survival following valve replacement for severe aortic regurgitation. Am Heart J 1981 Mar; 101(3): 300-8[Medline].
  • Grossman W, Jones D, McLaurin LP: Wall stress and patterns of hypertrophy in the human left ventricle. J Clin Invest 1975 Jul; 56(1): 56-64[Medline].
  • Hwang MH, Hammermeister KE, Oprian C, et al: Preoperative identification of patients likely to have left ventricular dysfunction after aortic valve replacement. Participants in the Veterans Administration Cooperative Study on Valvular Heart Disease. Circulation 1989 Sep; 80(3 Pt 1): I65-76[Medline].
  • Kawanishi DT, McKay CR, Chandraratna PA, et al: Cardiovascular response to dynamic exercise in patients with chronic symptomatic mild-to-moderate and severe aortic regurgitation. Circulation 1986 Jan; 73(1): 62-72[Medline].
  • Klodas E, Enriquez-Sarano M, Tajik AJ, et al: Optimizing timing of surgical correction in patients with severe aortic regurgitation: role of symptoms. J Am Coll Cardiol 1997 Sep; 30(3): 746-52[Medline].
  • Klodas E, Enriquez-Sarano M, Tajik AJ, et al: Aortic regurgitation complicated by extreme left ventricular dilation: long-term outcome after surgical correction. J Am Coll Cardiol 1996 Mar 1; 27(3): 670-7[Medline].
  • Krayenbuehl HP, Hess OM, Monrad ES, et al: Left ventricular myocardial structure in aortic valve disease before, intermediate, and late after aortic valve replacement. Circulation 1989 Apr; 79(4): 744-55[Medline].
  • Kumpuris AG, Quinones MA, Waggoner AD, et al: Importance of preoperative hypertrophy, wall stress and end-systolic dimension as echocardiographic predictors of normalization of left ventricular dilatation after valve replacement in chronic aortic insufficiency. Am J Cardiol 1982 Apr 1; 49(5): 1091-100[Medline].
  • Lin M, Chiang HT, Lin SL, et al: Vasodilator therapy in chronic asymptomatic aortic regurgitation: enalapril versus hydralazine therapy. J Am Coll Cardiol 1994 Oct; 24(4): 1046-53[Medline].
  • Niwa K, Perloff JK, Bhuta SM, et al: Structural abnormalities of great arterial walls in congenital heart disease: light and electron microscopic analyses. Circulation 2001 Jan 23; 103(3): 393-400[Medline][Full Text].
  • Scognamiglio R, Rahimtoola SH, Fasoli G, et al: Nifedipine in asymptomatic patients with severe aortic regurgitation and normal left ventricular function. N Engl J Med 1994 Sep 15; 331(11): 689-94[Medline].
  • Scognamiglio R, Negut C, Palisi M, et al: Long-term survival and functional results after aortic valve replacement in asymptomatic patients with chronic severe aortic regurgitation and left ventricular dysfunction. J Am Coll Cardiol 2005 Apr 5; 45(7): 1025-30[Medline].
  • Siemienczuk D, Greenberg B, Morris C, et al: Chronic aortic insufficiency: factors associated with progression to aortic valve replacement. Ann Intern Med 1989 Apr 15; 110(8): 587-92[Medline].
  • Singh JP, Evans JC, Levy D, et al: Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study). Am J Cardiol 1999 Mar 15; 83(6): 897-902[Medline].
  • Stone PH, Clark RD, Goldschlager N, et al: Determinants of prognosis of patients with aortic regurgitation who undergo aortic valve replacement. J Am Coll Cardiol 1984 May; 3(5): 1118-26[Medline].
  • Tornos MP, Olona M, Permanyer-Miralda G, et al: Clinical outcome of severe asymptomatic chronic aortic regurgitation: a long-term prospective follow-up study. Am Heart J 1995 Aug; 130(2): 333-9[Medline].
  • Turina J, Turina M, Rothlin M, Krayenbuehl HP: Improved late survival in patients with chronic aortic regurgitation by earlier operation. Circulation 1984 Sep; 70(3 Pt 2): I147-52[Medline].
  • Verheul HA, van den Brink RB, Bouma BJ, et al: Analysis of risk factors for excess mortality after aortic valve replacement. J Am Coll Cardiol 1995 Nov 1; 26(5): 1280-6[Medline].
  • Weber KT, Brilla CG: Pathological hypertrophy and cardiac interstitium. Fibrosis and renin- angiotensin-aldosterone system. Circulation 1991 Jun; 83(6): 1849-65[Medline].

Aortic Regurgitation excerpt